ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--

ImmunoGen, Inc. IMGN, a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

  • Leerink Partners 5th Annual Global Healthcare Conference
    2:40 pm ET, February 10
  • RBC Capital Markets Global Healthcare Conference
    11:30 am ET, February 23
  • Cowen and Company 36th Annual Health Care Conference
    9:20 am ET, March 8

The webcasts will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop anticancer therapies; it is used in Roche's marketed product, Kadcyla®. More information about the Company can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!